Our current work, along with the recently published studies, suggest a crucial role of BCL6 in rendering tumor cells more tolerant to treatments and a model in which multiple factors may contribute to BCL6 upregulation and BCL6-mediated signaling during this process. The gene discussed is BCL6; the disease is neoplasm.